Company News-Shenzhen MagicRNA Biotechnology Co., Ltd

MagicRNA to Present Breakthrough First-in-Human Data for In Vivo CAR-T Therapy in Autoimmune Disease at ASGCT 2026

SHENZHEN, China – 27April026 – Shenzhen MagicRNA Biotechnology Co., Ltd.(MagicRNA), a clinical-stage biotechnology company pioneering next-generation mRNA and lipid nanoparticle (LNP) delivery technologies, today announced that its lead program, “in VivoCD19 CAR T-cell The

2026-04-27

MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.

MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.·First-ever clinical data supporting safety and efficacy of in vivo CAR-T Therapy in refractorysystemic l

2025-09-18

Prof. Georg Schett Joins MagicRNA Bio’s Advisory Committee as Chief Medical Advisor

Breaking News | Pioneering Autoimmune CAR-T Therapy Expert, Internationally Renowned Rheumatologist Prof. Georg Schett Joins MagicRNABio’s Advisory Committee as Chief Medical AdvisorIn May 2025, Prof. Georg Schett, a pioneer in autoimmune CAR-T therapy and a globally renowned rheumatologist,

2025-06-16